Equities Analysts Set Expectations for Tectonic Therapeutic’s Q3 2024 Earnings (NASDAQ:TECX)

Tectonic Therapeutic (NASDAQ:TECX) – Equities research analysts at Leerink Partnrs reduced their Q3 2024 earnings estimates for shares of Tectonic Therapeutic in a research note issued to investors on Thursday, August 15th. Leerink Partnrs analyst D. Risinger now forecasts that the company will earn ($0.70) per share for the quarter, down from their previous forecast of ($0.50). Leerink Partnrs has a “Strong-Buy” rating on the stock. The consensus estimate for Tectonic Therapeutic’s current full-year earnings is ($4.24) per share. Leerink Partnrs also issued estimates for Tectonic Therapeutic’s Q4 2024 earnings at ($0.74) EPS, FY2024 earnings at ($3.33) EPS, Q1 2025 earnings at ($0.86) EPS, Q2 2025 earnings at ($0.83) EPS, Q3 2025 earnings at ($0.88) EPS, Q4 2025 earnings at ($0.98) EPS, FY2025 earnings at ($3.56) EPS, FY2026 earnings at ($2.58) EPS, FY2027 earnings at ($3.74) EPS and FY2028 earnings at ($3.90) EPS.

Several other analysts have also recently weighed in on the stock. TD Cowen started coverage on shares of Tectonic Therapeutic in a research report on Monday, June 24th. They set a “buy” rating on the stock. SVB Leerink started coverage on shares of Tectonic Therapeutic in a report on Wednesday, July 24th. They set an “outperform” rating and a $49.00 target price on the stock. Finally, Piper Sandler started coverage on shares of Tectonic Therapeutic in a report on Wednesday, June 26th. They set an “overweight” rating and a $76.00 target price on the stock.

Tectonic Therapeutic Stock Performance

Tectonic Therapeutic stock opened at $16.85 on Monday. The firm’s fifty day moving average is $16.59. The stock has a market cap of $756.46 million, a PE ratio of 24.42 and a beta of 2.63. Tectonic Therapeutic has a fifty-two week low of $12.12 and a fifty-two week high of $19.80.

Hedge Funds Weigh In On Tectonic Therapeutic

Institutional investors and hedge funds have recently made changes to their positions in the business. Renaissance Technologies LLC bought a new stake in Tectonic Therapeutic in the 2nd quarter worth $1,466,000. Affinity Asset Advisors LLC bought a new stake in Tectonic Therapeutic in the 2nd quarter worth $961,000. Farallon Capital Management LLC bought a new stake in Tectonic Therapeutic in the 2nd quarter worth $7,099,000. Atlas Venture Life Science Advisors LLC bought a new stake in Tectonic Therapeutic in the 2nd quarter worth $6,233,000. Finally, Acadian Asset Management LLC bought a new stake in Tectonic Therapeutic in the 2nd quarter worth $1,804,000. Institutional investors own 62.63% of the company’s stock.

About Tectonic Therapeutic

Avrobio, Inc is a bio-technology company. It develops step-change cell and gene therapies for the treatment of cancer and rare disease. The company operates primarily in the United States and Canada. Avrobio, Inc is based in MA, United States.